An Open-Label, Balanced, Randomized, Single-Dose, Two-Treatment, Single-Period, Parallel,Oral Bioequivalence Study of Sulfadoxine/ Pyrimethamine 500 mg / 25 mg Dispersible Tabletswith FANSIDARÂ® (Sulfadoxine/ Pyrimethamine) 500 mg / 25 mg Tablets of Akacia HealthcareLtd., in Healthy, Male and Non-Pregnant Female Adult, Human Subjects under FastingConditions.

Rena Exports0 sites0 target enrollmentStarted: TBDLast updated: November 24, 2021

Trial Snapshot

Phase: 未知
Status: Not yet recruiting
Sponsor

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Ba/be

Eligibility Criteria

Inclusion Criteria

•A subject should fulfill all the following
•1) criteria to be included in the present study:
•Willing to provide written informed consent for participation in the study and an ability
•to apprehend the nature and purpose of the study;
•2) Willing to be available for the entire study and to comply protocol requirements;
•3) Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age;
•4) Body mass index in the range of 18.50-30.00 kg/m2 (both inclusive); with minimum of
•45 kg weight.
•5) Normal health status as determined by baseline medical and medication history, at the
•time of screening and vital signs (supine/sitting blood pressure, pulse rate, respiratory
•rate and axillary temperature) measurements and clinical examination at the time
•screening as well as check-in during study;
•6) With normal or clinically non-significant laboratory values as determined by
•hematological and biochemistry tests and urine analysis;
•7)With a normal or clinically non-significant 12-lead ECG;
•8) Non-smokers and willing to abstain from chewing any tobacco containing product at
•least 72.00 hours prior to dosing and throughout the sampling points;
•9) Non-alcoholic;
•In case of female subjects:
•10) Negative urine pregnancy test during screening and negative serum Î²-HCG test at
•the time check-in;
•11) Female subjects with child bearing potential or those within their first two years of
•onset of menopausal syndrome must either abstain from sexual intercourse, or using
•acceptable methods of birth control for at least 15 days before 1st dosing till 15 days
•post last-dose/entire study period. (Acceptable birth control methods include barrier
•methods such as diaphragm/condom with spermicide or who are surgically sterile
•(bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been
•performed).

Exclusion Criteria

•A subject fulfilling any one of the following criteria should be excluded from the study:
•1) Any medical or surgical conditions, which might significantly interfere with the
•functioning of gastrointestinal tract and of bloodâ??forming organs;
•2) Significant history or current evidence of malignancy or chronic - infectious,
•cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic
•(endocrine), hematological, gastrointestinal, immunological or psychiatric diseases, or
•organ dysfunction;
•3) Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase
•deficiency or glucose-galactose malabsorption OR Subject has a history of severe
•allergy to milk protein;
•4) Any major illness or hospitalized within 90 days prior to the dosing;
•5) Any other clinical condition like diarrhea or vomiting within 3 days prior to dosing;
•6) Requiring medication for any ailment having enzyme-modifying activity in previous
•one month, prior to drug administration day and throughout the study duration;
•7) Use of any depot injection or an implant of any drug within 3 months prior to dosing
•and throughout the study duration;
•8) Use of any prescribed medication (including herbal drugs and vitamin supplements) 30
•days or within 5 half-lives of the drug, whichever is longer prior to dosing and
•throughout the study duration;
•9) Use of any OTC products within 14 days or within 5 half-lives of the drug, whichever is
•longer prior to dosing in the study duration and throughout the sampling time points;
•10) History or presence of significant gastric and/or duodenal ulceration;
•11) Difficulty in swallowing solids like tablets or capsules;
•12) Use of any recreational drug or history of drug addiction;
•13) Participated in any clinical investigation requiring repeated blood sampling, blood
•donation, or have blood loss of >500 mL in past 8 weeks or participated in any clinical
•study within the 90 days prior to dosing;
•14) Positive alcohol breath or urine drug of abuse tests during check-in in the study;
•15) Consumption of xanthine or its derivative containing food or beverages (e.g.
•chocolates, tea, coffee or cola drinks) within 48.00 hours prior to dosing in the study
•and throughout sampling time points;
•16) Consumption of grapefruit or its juice within 72.00 hours prior to dosing in the study
•and throughout sampling time points;
•17) Positive test for Human Immunodeficiency Virus (HIV) type I/II antibodies or
•Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibodies;
•18) Female subject whose menstruation cycle coincides with the study duration;
•Lactating or nursing female subjects;
•19) Female subjects using hormonal contraceptive (either oral/implants);
•20) History of allergy or hypersensitivity intolerance to Sulfadoxine/ Pyrimethamine (API)
•or its formulation excipients which, in the opinion of an investigator, would
•compromise the safety of the subject or the study;
•21) History of difficulty in accessibility of veins in arms.

Investigators

Sponsor

Rena Exports

Similar Trials

Completed

Phase 1

A clinical trial study to determine the oral bioavailability of curcuminoid capsules.

CTRI/2021/05/033903Pharmabase SA24

Completed

Not Applicable

Bioequivalence study of Cladribine 10 mg tablet in highly active relapsing multiple sclerosis patients

CTRI/2021/09/036201Hikma Pharmaceuticals40

Not yet recruiting

Phase 4

To Evaluate Oral Bioavailability Efficacy of Co Enzyme Q10 100mg in Healthy Human Adult Subjects

CTRI/2022/10/046730Doctors Best Inc

Not yet recruiting

Not Applicable

Bioavailability study of Amaryl (glimepiride) Tablet 1 mg in healthy, adult, human subjects under fed conditio

CTRI/2022/11/046993Sanofi Healthcare India Private Limited

Not yet recruiting

Phase 1

Comparative Bioavailability Study of Ketorolac TromethamineSublingual Tablet 10 mg in healthy human subjects

CTRI/2024/05/067180Troikaa Pharmaceuticals Ltd